Ophthalmology
Volume 114, Issue 6 , Pages 1053-1057, June 2007

Retinal Nerve Fiber Layer Damage as Assessed by Optical Coherence Tomography in Eyes with a Visual Field Defect Detectedby Frequency Doubling Technology Perimetry but Not by Standard Automated Perimetry

  • Tae-Woo Kim, MD

      Affiliations

    • Department of Ophthalmology, Seoul National University College of Medicine, Seoul National University Bundang Hospital, Seongnam, Korea.
  • ,
  • Linda M. Zangwill, PhD

      Affiliations

    • Hamilton Glaucoma Center, Department of Ophthalmology, University of California, San Diego, La Jolla, California.
  • ,
  • Christopher Bowd, PhD

      Affiliations

    • Hamilton Glaucoma Center, Department of Ophthalmology, University of California, San Diego, La Jolla, California.
  • ,
  • Pamela A. Sample, PhD

      Affiliations

    • Hamilton Glaucoma Center, Department of Ophthalmology, University of California, San Diego, La Jolla, California.
  • ,
  • Neha Shah, MD

      Affiliations

    • Hamilton Glaucoma Center, Department of Ophthalmology, University of California, San Diego, La Jolla, California.
  • ,
  • Robert N. Weinreb, MD

      Affiliations

    • Hamilton Glaucoma Center, Department of Ophthalmology, University of California, San Diego, La Jolla, California.
    • Corresponding Author InformationCorrespondence to Robert N. Weinreb, MD, Hamilton Glaucoma Center, University of California San Diego, 9500 Gilman Drive, Department 0946, La Jolla, CA 92093-0946.

Received 21 March 2006; accepted 13 September 2006. published online 17 January 2007.

Purpose

To determine whether the visual field (VF) loss detected by frequency doubling technology perimetry (FDT) but not by standard automated perimetry (SAP) is associated with retinal nerve fiber layer (RNFL) damage measured using optical coherence tomography (OCT).

Design

Observational case–control study.

Participants

Ninety-three subjects were recruited from the longitudinal University of California, San Diego, Diagnostic Innovations in Glaucoma Study.

Methods

All participants had ≥2 reliable SAP–Swedish Interactive Testing Algorithm and FDT 24-2 tests and at least one Stratus OCT test, all conducted within a 6-month time window.

Main Outcome Measures

Retinal nerve fiber layer thickness measured with OCT and the number of sectors with OCT-measured RNFL thickness lower than the 95% confidence interval (CI) or 99% CI based on the instrument’s normative database.

Results

Compared with those with normal SAP and FDT results, a significantly higher proportion of subjects with normal SAP and abnormal FDT results had OCT-measured RNFL thickness outside 95% limits in the inferior and superior quadrants (P = 0.048) and outside 99% limits in the inferior quadrant (P = 0.010).

Conclusions

When SAP is within normal range, some patients with VF loss detected by FDT show a decreased RNFL thickness, possibly indicating the presence of glaucomatous damage. These results support the validity of FDT as a tool to detect early glaucoma.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 Manuscript no. 2006-348.

 Disclosure: research support from Carl Zeiss Meditec (LMZ, PAS, RNW), Heidelberg Engineering (LMZ, RNW), Welch-Allyn (PAS), and Haag-Streit (PAS). Honoraria from Heidelberg Engineering (LMZ, RNW) and Carl Zeiss Meditec (RNW).

 Supported by the National Institutes of Health, Bethesda, Maryland (grant nos. EY11008 [LMZ], EY08208 [PAS]). Participant retention incentive grants in the form of glaucoma medication at no cost: Alcon Laboratories, Inc., Fort Worth, Texas; Allergan, Irvine, California; Pfizer, Inc., New York, New York; and Santen, Inc., Napa, California.

PII: S0161-6420(06)01313-3

doi:10.1016/j.ophtha.2006.09.015

Ophthalmology
Volume 114, Issue 6 , Pages 1053-1057, June 2007